Olopatadine/mometasone combination nasal spray in allergic rhinitis: a profile of its use
- PDF / 826,052 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 111 Downloads / 203 Views
ADIS DRUG Q&A
Olopatadine/mometasone combination nasal spray in allergic rhinitis: a profile of its use Yvette N. Lamb1 Published online: 27 September 2020 © Springer Nature Switzerland AG 2020
Abstract Olopatadine/mometasone furoate combination nasal spray (Ryaltris®; referred to hereafter as olopatadine/mometasone), a convenient fixed-dose combination (FDC) of the antihistamine olopatadine and the corticosteroid mometasone furoate, is approved in Australia for the treatment of symptoms associated with allergic rhinitis (AR) and rhinoconjunctivitis in patients 12 years of age and older. Olopatadine/mometasone is an effective treatment for seasonal and perennial AR, providing statistically significant and clinically meaningful relief of nasal symptoms relative to monocomponents and/or placebo in clinical trials. Ocular symptoms of AR were also improved with olopatadine/mometasone. Benefits of olopatadine/mometasone were maintained over 52 weeks of treatment in adults and adolescents with perennial AR. Olopatadine/mometasone is generally well tolerated, with most treatment-emergent adverse events being of mild to moderate severity.
Adis evaluation of olopatadine/mometasone in the management of allergic rhinitis Combines two first-line treatments with distinct mechanisms of action into an FDC nasal spray Rapidly improves symptoms of seasonal AR Provides effective long-term relief of nasal symptoms of perennial AR Improves quality of life of patients affected by AR Generally well tolerated, with no systemic adverse effects
Enhanced material for this Adis Drug Q&A can be found at https ://doi.org/10.6084/m9.figshare.12845843. * Yvette N. Lamb [email protected] 1
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand
Vol:.(1234567890)
What was the rationale for developing a fixed‑dose combination of olopatadine and mometasone in allergic rhinitis? Allergic rhinitis (AR) is characterised by immunoglobulin E (IgE)-mediated inflammation of the nasal mucous membranes following the inhalation of allergens [1, 2]. Seasonal AR can be caused by a range of outdoor allergens (e.g. pollens), while perennial AR is most often caused by indoor allergens (e.g. house dust mites, animal dander) [3]. Symptoms of AR can be intermittent (present 4 weeks/year), and include nasal congestion, nasal drip (rhinorrhoea), nasal itching and sneezing [2, 3]. Redness, watering and itching of the eyes (allergic conjunctivitis) frequently accompanies AR [1, 4]. A global health problem with considerable financial impact, AR represents one of the most prevalent chronic diseases in adults and children [2, 5]. In Australia, for example, AR affects ≈ 19% of the population [6]. Various over-the-counter and prescription medications are available for the treatment of AR. Intranasal corticosteroids and (to a somewhat lesser extent [7]) antihistamines are effective in relieving symptoms [2, 8]. Antihistamines have a rapid onset of action and can thus provide immediate symptom relief. In comparison, corticosteroids have a lo
Data Loading...
